Risk factors of cytomegalovirus infection in patients undergoing liver transplantation

doi:10.3969/j.issn.1006-7795.2021.04.025

Abstract

Abstract: Objective To look for the risk factors of cytomegalovirus (CMV) infection by analyzing the characteristics of hospitalized liver transplantation patients. Methods Retrospective analysis was conducted on the clinical data of 134 patients with CMV laboratory test results who received liver transplantation in Department of Hepatobiliary and Pancreaticosplenic Surgery of Beijing Chaoyang Hospital between December 2016 to February 2019, including 113 males and 21 females, with an average age of (52±10) years. The patients were divided into the CMV infection group (n=24) and the control group (n=110) according to the presence of CMV infection within 3 months after surgery. T test, Mann-Whitney U test and Chi-square test were used for single factor analysis, and Logistic regression analysis was used for multivariate analysis to determine the risk factors of CMV infection in patients after liver transplantation. Results The results of univariate analysis showed that the history of age (P=0.005), model for end-stage liver disease (MELD) score (P=0.001), Child-Pugh score (P=0.048), total bilirubin (P=0.002), international normalized ratio (INR) (P=0.002), blood ammonia (P=0.040) and ascites(P=0.042), operation method (P=0.023), intraoperative bleeding volume (P=0.006), blood transfusion volume (P=0.004) and postoperative intensive care unit (ICU) monitoring time (P=0.016) were risk factors of CMV infection. The results of multivariate analysis suggested that MELD score (P=0.007, 95% CI: 1.027-1.187) may be an independent risk factor of CMV infection. The use of immunosuppressive agents, including calcineurin inhibitors (CNI), mycophenolate mofetils (MMF), glucocorticoids, and polyclonal antibodies were not associated with early postoperative CMV infection in patients with liver transplantation. Conclusion High MELD score may be an independent risk factor for CMV infection after liver transplantation. Immunosuppressive agents are not risk factors for early postoperative CMV infection in patients after liver transplantation.

Key words: liver transplantation, cytomegalovirus, immunosuppressive agents, risk factors

CLC Number:

Sun Ximu, Wang Huaguang, Zhao Xin, Lyu Shaocheng, He Qiang, Liu Lihong. Risk factors of cytomegalovirus infection in patients undergoing liver transplantation[J]. Journal of Capital Medical University, 2021, 42(4): 664-671.

0
/ / Recommend

Add to citation manager EndNote|Reference Manager|ProCite|BibTeX|RefWorks

URL: https://journal03.magtech.org.cn/Jweb_sdykdxxb/EN/10.3969/j.issn.1006-7795.2021.04.025

https://journal03.magtech.org.cn/Jweb_sdykdxxb/EN/Y2021/V42/I4/664

References

[1] 曾庆贺,董加秀,孟艳,等. 人巨细胞病毒感染的流行病学研究进展[J]. 山东医药, 2017, 57(12): 110-116.
[2] Belga S, MacDonald C, Chiang D, et al. Donor graft CMV-serostatus and the risk of arterial and venous thrombotic events in seronegative recipients after non-thoracic solid organ transplantation[J]. Clin Infect Dis, 2020,72(5):845-852.
[3] Griffiths P D, Grundy J E. Molecular biology and immunology of cytomegalovirus[J]. Biochem J, 1987, 241(2):313-324.
[4] Herman D, Han H. Cytomegalovirus in liver transplant recipients[J]. Curr Opin Organ Transplant, 2017, 22(4): 345-350.
[5] Eid A J, Razonable R R. New developments in the management of cytomegalovirus infection after solid organ transplantation[J]. Drugs, 2010, 70(8):965-981.
[6] Van Delden C, Stampf S, Hirsch H H, et al. Burden and timeline of infectious diseases in the first year after solid organ transplantation in the swiss transplant cohort study[J]. Clin Infect Dis, 2020,71(7):e159-e169.
[7] Razonable R R, Humar A. Cytomegalovirus in solid organ transplant recipients-Guidelines of the American Society of Transplantation Infectious Diseases Community of Practice[J]. Clin Transplant, 2019, 33(9): e13512.
[8] 中华医学会器官移植学分会. 器官移植受者巨细胞病毒感染临床诊疗规范(2019版)[J]. 器官移植, 2019, 10(2):142-148.
[9] Kotton C N, Kumar D, Caliendo A M, et al. Updated international consensus guidelines on the management of cytomegalovirus in solid-organ transplantation[J]. Transplantation, 2013, 96(4):333-360.
[10] Razonable R R. Cytomegalovirus infection after liver transplantation: current concepts and challenges[J]. World J Gastroenterol, 2008, 14(31): 4849-4860.
[11] Child C G, Turcotte J G. Surgery and portal hypertension[J]. Major Probl Clin Surg, 1964,1:1-85.
[12] Pugh R N, Murray-Lyon I M, Dawson J L,et al. Transection of the oesophagus for bleeding oesophageal varices[J]. Br J Surg, 1973,60(8):646-649.
[13] Peng Y, Qi X, Guo X. Child-Pugh versus MELD score for the assessment of prognosis in liver cirrhosis: a systematic review and meta-analysis of observational studies[J]. Medicine(Baltimore), 2016, 95(8): e2877.
[14] Selimoğlu M A, Kaya S, Güngör Ş, et al. Infection risk after paediatric liver transplantation[J]. Turk J Pediatr, 2020, 62(1): 46-52.
[15] Kanter J, Pallardó L, Gavela E,et al. Cytomegalovirus infection renal transplant recipients: risk factors and outcome[J]. Transplant Proc, 2009,41(6):2156-2158.
[16] Hemmersbach-Miller M, Alexander B D, Pieper C F, et al. Age matters: older age as a risk factor for CMV reactivation in the CMV serostatus-positive kidney transplant recipient. Eur J Clin Microbiol Infect Dis, 2020,39(3):455-463.
[17] Liu P Y, Cheng S B, Lin C C, et al. Cytomegalovirus disease after liver transplantation: a nationwide population-based study[J]. Transplant Proc, 2014, 46(3): 832-834.
[18] 易永祥. 乙型肝炎病毒的分子流行病学研究进展[J]. 新发传染病电子杂志, 2020, 5(1): 1-7.
[19] 中国医师协会器官移植医师分会,中华医学会器官移植学分会. 中国肝癌肝移植临床实践指南(2018版)[J]. 临床肝胆病杂志, 2019, 35(2): 275-280.
[20] 刘亚萍,赵倩,殷燕,等.慢性乙型肝炎患者血清GP73、HA水平与HBV DNA载量及肝功能的相关性研究[J].临床误诊误治,2019,32(9):48-53.
[21] 吴丹丹,张超群,马士朝,等.应用逆转录-环介导等温扩增技术检测乙型肝炎病毒RNA方法的建立[J].解放军医药杂志,2019,31(1):107-112.
[22] 赵宏,范骏,胡建华,等. HBV感染对肝移植术后巨细胞病毒感染的影响[J]. 中华微生物学和免疫学杂志, 2010, 30(2):150-153.
[23] 曹华军,张卓然. 巨细胞病毒与乙肝病毒持续感染的关系[J]. 临床肝胆病杂志, 2006, 22(5): 336-338.
[24] 杜冀晖,苏卓娃,张厚德. 乙型肝炎患者人类巨细胞病毒感染再活化研究[J]. 广东医学, 2001, 22(4): 320-321.
[25] 岳竹,李昂,刘培,等.肝移植术后急性肾损伤的发生率及危险因素[J].首都医科大学学报,2018,39(1):14-20.
[26] 郭瑞,李晓航,李峰,等.肝移植术中入肝血流量对术后早期移植物功能不全的临床意义[J].中国医科大学学报,2019,48(3):240-244.
[27] 王博文,张佳林,李晓航,等.合并受体肝动脉变异肝移植肝动脉重建22例临床分析[J].中国医科大学学报,2018,47(11):975-979.
[28] Yadav S K, Saigal S, Choudhary N S, et al. Cytomegalovirus infection in liver transplant recipients: current approach to diagnosis and management[J]. J Clin Exp Hepatol, 2017, 7(2): 144-151.
[29] Dogan N, Husing-Kabar A, Schmidt H H, et al. Acute allograft rejection in liver transplant recipients: Incidence, risk factors, treatment success, and impact on graft failure[J]. J Int Med Res, 2018, 46(9): 3979-3990.
[30] Kawano Y, Mizuta K, Sanada Y, et al. Risk factors of cytomegalovirus infection after pediatric liver transplantation[J]. Transplant Proc, 2014, 46(10): 3543-3547.
[31] 托娅,张爱梅. 实体器官移植受者巨细胞病毒感染的危险因素及实验室诊断方法[J]. 中国疗养医学, 2009, 18(1): 60-61.
[32] Brennan D C, Daller J A, Lake K D, et al. Rabbit antithymocyte globulin versus basiliximab in renal transplantation[J]. N Engl J Med, 2006, 355(19): 1967-1977.
[33] Kim S J, Rhu J, Yoo H, et al. Outcome comparison between low-dose rabbit anti-thymocyte globulin and basiliximab in low-risk living donor kidney transplantation[J]. J Clin Med, 2020, 9(5):1320.
[34] Pascual J, Royuela A, Fernandez A M, et al. Role of mTOR inhibitors for the control of viral infection in solid organ transplant recipients[J]. Transpl Infect Dis, 2016, 18(6): 819-831.
[35] 佚名. 西罗莫司对实体器官移植后巨细胞病毒感染的预防和治疗作用[J]. 中华器官移植杂志, 2008, 29(9): 576.